Loading…
Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignancies
In this prospective randomized study we evaluated the effect of risedronate, an aminobisphosphonate, on bone mass and turnover in patients who had undergone allogeneic stem cell transplant (SCT) for hematological malignancies. Thirty-four patients (18 females, 16 males, age 32+/-10 years) with bone...
Saved in:
| Published in: | Osteoporosis international 2003-12, Vol.14 (12), p.1013-1019 |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c387t-9d8a009127e9596d880609b72d5319ff7bb32ba8a292ff6d7331349a4d5f3733 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c387t-9d8a009127e9596d880609b72d5319ff7bb32ba8a292ff6d7331349a4d5f3733 |
| container_end_page | 1019 |
| container_issue | 12 |
| container_start_page | 1013 |
| container_title | Osteoporosis international |
| container_volume | 14 |
| creator | TAUCHMANOVA, L SELLERI, C ESPOSITO, M DI SOMMA, C ORIO, F. JR BIFULCO, G PALOMBA, S LOMBARDI, G ROTOLI, B COLAO, A |
| description | In this prospective randomized study we evaluated the effect of risedronate, an aminobisphosphonate, on bone mass and turnover in patients who had undergone allogeneic stem cell transplant (SCT) for hematological malignancies. Thirty-four patients (18 females, 16 males, age 32+/-10 years) with bone mineral density (BMD) |
| doi_str_mv | 10.1007/s00198-003-1520-2 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_19271270</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19271270</sourcerecordid><originalsourceid>FETCH-LOGICAL-c387t-9d8a009127e9596d880609b72d5319ff7bb32ba8a292ff6d7331349a4d5f3733</originalsourceid><addsrcrecordid>eNpdkU1rHSEUhqU0NLdpf0A3RQrtztSPcdRlE_oFgWyy6E7OzOiNYUZv1UnpH-jvjsO9EOhKlOd9PZwHoXeMXjJK1edCKTOaUCoIk5wS_gLtWCcE4aaXL9GOGqGI6divc_S6lAfaMsaoV-icdZIpadQO_bty0fkwBphxzQ7q4mLFf0K9xzkUN-UUoTocIp5T3JPq8oLLmh_DY8oFg28PGOY57VtNGHGpbsGjm7cyiOUwQ6xQQ4rYp4zv3QI1NTiM7bsF5rCPEMfgyht05mEu7u3pvEB3377eXf8gN7fff15_uSGj0KoSM2mg1DCunJGmn7SmPTWD4pMUzHivhkHwATRww73vJyUEE52BbpJetMsF-nSsPeT0e3Wl2iWUbVyILq3FMsNVK6cN_PAf-JDWHNtoljOtO93xrkHsCI05lZKdt4ccFsh_LaN2E2SPgmwTZDdBlrfM-1PxOixuek6cjDTg4wmA0rbk87ag8sxJIbmgvXgCYBma-g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>218848424</pqid></control><display><type>article</type><title>Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignancies</title><source>Springer Nature</source><creator>TAUCHMANOVA, L ; SELLERI, C ; ESPOSITO, M ; DI SOMMA, C ; ORIO, F. JR ; BIFULCO, G ; PALOMBA, S ; LOMBARDI, G ; ROTOLI, B ; COLAO, A</creator><creatorcontrib>TAUCHMANOVA, L ; SELLERI, C ; ESPOSITO, M ; DI SOMMA, C ; ORIO, F. JR ; BIFULCO, G ; PALOMBA, S ; LOMBARDI, G ; ROTOLI, B ; COLAO, A</creatorcontrib><description>In this prospective randomized study we evaluated the effect of risedronate, an aminobisphosphonate, on bone mass and turnover in patients who had undergone allogeneic stem cell transplant (SCT) for hematological malignancies. Thirty-four patients (18 females, 16 males, age 32+/-10 years) with bone mineral density (BMD) </=-1.5 SD as a T-score at least 6 months after SCT were treated with calcium 1 g/day and vitamin D 800 IU/day and randomized to receive ( n=17, group 1) or not receive ( n=17, group 2) oral risedronate 5 mg/day. The duration of treatment was 12 months. After 6 months, lumbar BMD increased by 4.4+/-1.6% in patients of group 1 and decreased by 4.3+/-1.5% in those of group 2 ( P<0.05); at the femoral neck, BMD did not change significantly in patients of group 1 (+1.2+/-1.2%), while it decreased in those of group 2 (-4.3+/-2.1%; P<0.05). After 12 months, lumbar BMD further increased (+5.9+/-1.7%, P<0.05), compared to baseline in group 1 and slightly increased (+1.1+/-1.4%) in group 2. No further changes were observed at femoral neck in both groups. In conclusion, treatment with risedronate for 12 months increased BMD significantly at the lumbar spine and prevented further bone loss at the femoral neck in long-term survivors after allo-SCT.</description><identifier>ISSN: 0937-941X</identifier><identifier>EISSN: 1433-2965</identifier><identifier>DOI: 10.1007/s00198-003-1520-2</identifier><identifier>PMID: 14517597</identifier><language>eng</language><publisher>London: Springer</publisher><subject>Administration, Oral ; Adult ; Biological and medical sciences ; Bisphosphonates ; Body mass index ; Bone density ; Bone Density - drug effects ; Bone Density Conservation Agents - administration & dosage ; Bone Density Conservation Agents - adverse effects ; Bones, joints and connective tissue. Antiinflammatory agents ; Calcium - administration & dosage ; Creatinine ; Drug Administration Schedule ; Etidronic Acid - administration & dosage ; Etidronic Acid - adverse effects ; Etidronic Acid - analogs & derivatives ; Female ; Femur Neck - drug effects ; Femur Neck - physiopathology ; Gynecology ; Hematologic Neoplasms - surgery ; Hematology ; Hormone replacement therapy ; Humans ; Lumbar Vertebrae - drug effects ; Lumbar Vertebrae - physiopathology ; Male ; Medical sciences ; Metabolism ; Obstetrics ; Osteocalcin - blood ; Osteoporosis ; Osteoporosis - drug therapy ; Osteoporosis - metabolism ; Pharmacology. Drug treatments ; Prospective Studies ; Risedronate Sodium ; Stem cell transplantation ; Stem Cell Transplantation - methods ; Time Factors ; Treatment Outcome ; Vitamin D - administration & dosage</subject><ispartof>Osteoporosis international, 2003-12, Vol.14 (12), p.1013-1019</ispartof><rights>2004 INIST-CNRS</rights><rights>International Osteoporosis Foundation and National Osteoporosis Foundation 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c387t-9d8a009127e9596d880609b72d5319ff7bb32ba8a292ff6d7331349a4d5f3733</citedby><cites>FETCH-LOGICAL-c387t-9d8a009127e9596d880609b72d5319ff7bb32ba8a292ff6d7331349a4d5f3733</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15352306$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14517597$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>TAUCHMANOVA, L</creatorcontrib><creatorcontrib>SELLERI, C</creatorcontrib><creatorcontrib>ESPOSITO, M</creatorcontrib><creatorcontrib>DI SOMMA, C</creatorcontrib><creatorcontrib>ORIO, F. JR</creatorcontrib><creatorcontrib>BIFULCO, G</creatorcontrib><creatorcontrib>PALOMBA, S</creatorcontrib><creatorcontrib>LOMBARDI, G</creatorcontrib><creatorcontrib>ROTOLI, B</creatorcontrib><creatorcontrib>COLAO, A</creatorcontrib><title>Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignancies</title><title>Osteoporosis international</title><addtitle>Osteoporos Int</addtitle><description>In this prospective randomized study we evaluated the effect of risedronate, an aminobisphosphonate, on bone mass and turnover in patients who had undergone allogeneic stem cell transplant (SCT) for hematological malignancies. Thirty-four patients (18 females, 16 males, age 32+/-10 years) with bone mineral density (BMD) </=-1.5 SD as a T-score at least 6 months after SCT were treated with calcium 1 g/day and vitamin D 800 IU/day and randomized to receive ( n=17, group 1) or not receive ( n=17, group 2) oral risedronate 5 mg/day. The duration of treatment was 12 months. After 6 months, lumbar BMD increased by 4.4+/-1.6% in patients of group 1 and decreased by 4.3+/-1.5% in those of group 2 ( P<0.05); at the femoral neck, BMD did not change significantly in patients of group 1 (+1.2+/-1.2%), while it decreased in those of group 2 (-4.3+/-2.1%; P<0.05). After 12 months, lumbar BMD further increased (+5.9+/-1.7%, P<0.05), compared to baseline in group 1 and slightly increased (+1.1+/-1.4%) in group 2. No further changes were observed at femoral neck in both groups. In conclusion, treatment with risedronate for 12 months increased BMD significantly at the lumbar spine and prevented further bone loss at the femoral neck in long-term survivors after allo-SCT.</description><subject>Administration, Oral</subject><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Bisphosphonates</subject><subject>Body mass index</subject><subject>Bone density</subject><subject>Bone Density - drug effects</subject><subject>Bone Density Conservation Agents - administration & dosage</subject><subject>Bone Density Conservation Agents - adverse effects</subject><subject>Bones, joints and connective tissue. Antiinflammatory agents</subject><subject>Calcium - administration & dosage</subject><subject>Creatinine</subject><subject>Drug Administration Schedule</subject><subject>Etidronic Acid - administration & dosage</subject><subject>Etidronic Acid - adverse effects</subject><subject>Etidronic Acid - analogs & derivatives</subject><subject>Female</subject><subject>Femur Neck - drug effects</subject><subject>Femur Neck - physiopathology</subject><subject>Gynecology</subject><subject>Hematologic Neoplasms - surgery</subject><subject>Hematology</subject><subject>Hormone replacement therapy</subject><subject>Humans</subject><subject>Lumbar Vertebrae - drug effects</subject><subject>Lumbar Vertebrae - physiopathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Metabolism</subject><subject>Obstetrics</subject><subject>Osteocalcin - blood</subject><subject>Osteoporosis</subject><subject>Osteoporosis - drug therapy</subject><subject>Osteoporosis - metabolism</subject><subject>Pharmacology. Drug treatments</subject><subject>Prospective Studies</subject><subject>Risedronate Sodium</subject><subject>Stem cell transplantation</subject><subject>Stem Cell Transplantation - methods</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Vitamin D - administration & dosage</subject><issn>0937-941X</issn><issn>1433-2965</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><recordid>eNpdkU1rHSEUhqU0NLdpf0A3RQrtztSPcdRlE_oFgWyy6E7OzOiNYUZv1UnpH-jvjsO9EOhKlOd9PZwHoXeMXjJK1edCKTOaUCoIk5wS_gLtWCcE4aaXL9GOGqGI6divc_S6lAfaMsaoV-icdZIpadQO_bty0fkwBphxzQ7q4mLFf0K9xzkUN-UUoTocIp5T3JPq8oLLmh_DY8oFg28PGOY57VtNGHGpbsGjm7cyiOUwQ6xQQ4rYp4zv3QI1NTiM7bsF5rCPEMfgyht05mEu7u3pvEB3377eXf8gN7fff15_uSGj0KoSM2mg1DCunJGmn7SmPTWD4pMUzHivhkHwATRww73vJyUEE52BbpJetMsF-nSsPeT0e3Wl2iWUbVyILq3FMsNVK6cN_PAf-JDWHNtoljOtO93xrkHsCI05lZKdt4ccFsh_LaN2E2SPgmwTZDdBlrfM-1PxOixuek6cjDTg4wmA0rbk87ag8sxJIbmgvXgCYBma-g</recordid><startdate>20031201</startdate><enddate>20031201</enddate><creator>TAUCHMANOVA, L</creator><creator>SELLERI, C</creator><creator>ESPOSITO, M</creator><creator>DI SOMMA, C</creator><creator>ORIO, F. JR</creator><creator>BIFULCO, G</creator><creator>PALOMBA, S</creator><creator>LOMBARDI, G</creator><creator>ROTOLI, B</creator><creator>COLAO, A</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7RV</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20031201</creationdate><title>Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignancies</title><author>TAUCHMANOVA, L ; SELLERI, C ; ESPOSITO, M ; DI SOMMA, C ; ORIO, F. JR ; BIFULCO, G ; PALOMBA, S ; LOMBARDI, G ; ROTOLI, B ; COLAO, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c387t-9d8a009127e9596d880609b72d5319ff7bb32ba8a292ff6d7331349a4d5f3733</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Administration, Oral</topic><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Bisphosphonates</topic><topic>Body mass index</topic><topic>Bone density</topic><topic>Bone Density - drug effects</topic><topic>Bone Density Conservation Agents - administration & dosage</topic><topic>Bone Density Conservation Agents - adverse effects</topic><topic>Bones, joints and connective tissue. Antiinflammatory agents</topic><topic>Calcium - administration & dosage</topic><topic>Creatinine</topic><topic>Drug Administration Schedule</topic><topic>Etidronic Acid - administration & dosage</topic><topic>Etidronic Acid - adverse effects</topic><topic>Etidronic Acid - analogs & derivatives</topic><topic>Female</topic><topic>Femur Neck - drug effects</topic><topic>Femur Neck - physiopathology</topic><topic>Gynecology</topic><topic>Hematologic Neoplasms - surgery</topic><topic>Hematology</topic><topic>Hormone replacement therapy</topic><topic>Humans</topic><topic>Lumbar Vertebrae - drug effects</topic><topic>Lumbar Vertebrae - physiopathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Metabolism</topic><topic>Obstetrics</topic><topic>Osteocalcin - blood</topic><topic>Osteoporosis</topic><topic>Osteoporosis - drug therapy</topic><topic>Osteoporosis - metabolism</topic><topic>Pharmacology. Drug treatments</topic><topic>Prospective Studies</topic><topic>Risedronate Sodium</topic><topic>Stem cell transplantation</topic><topic>Stem Cell Transplantation - methods</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Vitamin D - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>TAUCHMANOVA, L</creatorcontrib><creatorcontrib>SELLERI, C</creatorcontrib><creatorcontrib>ESPOSITO, M</creatorcontrib><creatorcontrib>DI SOMMA, C</creatorcontrib><creatorcontrib>ORIO, F. JR</creatorcontrib><creatorcontrib>BIFULCO, G</creatorcontrib><creatorcontrib>PALOMBA, S</creatorcontrib><creatorcontrib>LOMBARDI, G</creatorcontrib><creatorcontrib>ROTOLI, B</creatorcontrib><creatorcontrib>COLAO, A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Physical Education Index</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Osteoporosis international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>TAUCHMANOVA, L</au><au>SELLERI, C</au><au>ESPOSITO, M</au><au>DI SOMMA, C</au><au>ORIO, F. JR</au><au>BIFULCO, G</au><au>PALOMBA, S</au><au>LOMBARDI, G</au><au>ROTOLI, B</au><au>COLAO, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignancies</atitle><jtitle>Osteoporosis international</jtitle><addtitle>Osteoporos Int</addtitle><date>2003-12-01</date><risdate>2003</risdate><volume>14</volume><issue>12</issue><spage>1013</spage><epage>1019</epage><pages>1013-1019</pages><issn>0937-941X</issn><eissn>1433-2965</eissn><abstract>In this prospective randomized study we evaluated the effect of risedronate, an aminobisphosphonate, on bone mass and turnover in patients who had undergone allogeneic stem cell transplant (SCT) for hematological malignancies. Thirty-four patients (18 females, 16 males, age 32+/-10 years) with bone mineral density (BMD) </=-1.5 SD as a T-score at least 6 months after SCT were treated with calcium 1 g/day and vitamin D 800 IU/day and randomized to receive ( n=17, group 1) or not receive ( n=17, group 2) oral risedronate 5 mg/day. The duration of treatment was 12 months. After 6 months, lumbar BMD increased by 4.4+/-1.6% in patients of group 1 and decreased by 4.3+/-1.5% in those of group 2 ( P<0.05); at the femoral neck, BMD did not change significantly in patients of group 1 (+1.2+/-1.2%), while it decreased in those of group 2 (-4.3+/-2.1%; P<0.05). After 12 months, lumbar BMD further increased (+5.9+/-1.7%, P<0.05), compared to baseline in group 1 and slightly increased (+1.1+/-1.4%) in group 2. No further changes were observed at femoral neck in both groups. In conclusion, treatment with risedronate for 12 months increased BMD significantly at the lumbar spine and prevented further bone loss at the femoral neck in long-term survivors after allo-SCT.</abstract><cop>London</cop><pub>Springer</pub><pmid>14517597</pmid><doi>10.1007/s00198-003-1520-2</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0937-941X |
| ispartof | Osteoporosis international, 2003-12, Vol.14 (12), p.1013-1019 |
| issn | 0937-941X 1433-2965 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_19271270 |
| source | Springer Nature |
| subjects | Administration, Oral Adult Biological and medical sciences Bisphosphonates Body mass index Bone density Bone Density - drug effects Bone Density Conservation Agents - administration & dosage Bone Density Conservation Agents - adverse effects Bones, joints and connective tissue. Antiinflammatory agents Calcium - administration & dosage Creatinine Drug Administration Schedule Etidronic Acid - administration & dosage Etidronic Acid - adverse effects Etidronic Acid - analogs & derivatives Female Femur Neck - drug effects Femur Neck - physiopathology Gynecology Hematologic Neoplasms - surgery Hematology Hormone replacement therapy Humans Lumbar Vertebrae - drug effects Lumbar Vertebrae - physiopathology Male Medical sciences Metabolism Obstetrics Osteocalcin - blood Osteoporosis Osteoporosis - drug therapy Osteoporosis - metabolism Pharmacology. Drug treatments Prospective Studies Risedronate Sodium Stem cell transplantation Stem Cell Transplantation - methods Time Factors Treatment Outcome Vitamin D - administration & dosage |
| title | Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignancies |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T19%3A14%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Beneficial%20treatment%20with%20risedronate%20in%20long-term%20survivors%20after%20allogeneic%20stem%20cell%20transplantation%20for%20hematological%20malignancies&rft.jtitle=Osteoporosis%20international&rft.au=TAUCHMANOVA,%20L&rft.date=2003-12-01&rft.volume=14&rft.issue=12&rft.spage=1013&rft.epage=1019&rft.pages=1013-1019&rft.issn=0937-941X&rft.eissn=1433-2965&rft_id=info:doi/10.1007/s00198-003-1520-2&rft_dat=%3Cproquest_cross%3E19271270%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c387t-9d8a009127e9596d880609b72d5319ff7bb32ba8a292ff6d7331349a4d5f3733%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=218848424&rft_id=info:pmid/14517597&rfr_iscdi=true |